NCCN Clinical Practice Guidelines in Oncology (NCCN …
https://www2.tri-kobe.org/nccn/guideline/urological/english/prostate.pdf
ContinueThomas A. Farrington ¥ Prostate Health Education Network (PHEN)PROS-F (2 of 5)PROS-F (3 of 5)PROS-1PROS-2Changed: Consider Repeat mpMRI no more often than every 12 mo[PROS-2])."PROS-D (1 of 5)PROS-D (3 of 5)INITIAL PROSTATE CANCER DIAGNOSISa,b<10 yf Observations See Monitoring (PROS-11)See Monitoring (PROS-11)Observations ADTu (category 1) ± EBRTq (category 2B) Recurrence or (PROS-13) ≤5 y and or Observations asymptomatic ADTu,cc or EBRTq,cc z RTOG-ASTRO (Radiation Therapy Oncology Group - American Society forEBRTq + ADTu (preferred)EBRTq ± ADTuSee Systemic Therapy for Castration-Naive Disease (PROS-14)jjSee PROS-18ddd,eeePrior therapy docetaxel ddd,hhhSUBSEQUENT TREATMENT (category 2B)Goals of ImagingUltrasoundBone ImagingPRINCIPLES OF IMAGINGDefinitive Radiation Therapy General PrinciplesPRINCIPLES OF RADIATION THERAPYSalvage BrachytherapyPelvic Lymph Node DissectionRadical ProstatectomyLiterature Search Criteria and Guidelines Update MethodologyRisks of ImagingRadiation Therapy Proton Therapy Palliative ADTChemotherapy and ImmunotherapySummaryBone scans are helpful to monitor metastatic prostate cancer to determine the clinical benefit of systemic therapy. However, new lesions seen on an initial post-treatment bone scan, compared to the pre-treatment baseline scan, may not indicate disease progression. New lesions in the setting of a falling PSA or soft tissue response and in the absenc...See more on www2.tri-kobe.org Bone scans are helpful to monitor metastatic prostate cancer to determine the clinical benefit of systemic therapy. However, new lesions seen on an initial post-treatment bone scan, compared to the pre-treatment baseline scan, may not indicate disease progression. New lesions in the setting of a falling PSA or soft tissue response and in the absenc... File Size: 1MB Page Count: 166
Bone scans are helpful to monitor metastatic prostate cancer to determine the clinical benefit of systemic therapy. However, new lesions seen on an initial post-treatment bone scan, compared to the pre-treatment baseline scan, may not indicate disease progression. New lesions in the setting of a falling PSA or soft tissue response and in the absenc...
File Size: 1MB
Page Count: 166
DA: 48 PA: 55 MOZ Rank: 42 Up or Down: Up
